Announced Tue, 28 Jul · 10:49 IST
Board Meeting on Aug 6 2026 to Consider Q1 FY27 Results
Board & Shareholder Meetings View source PDF
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve
Awaiting price reaction for this filing.
AI summary
Krebs Biochemicals & Industries has informed BSE that the Board of Directors will meet on Thursday, August 6, 2026 to consider and adopt the unaudited financial results for Q1 ended June 30, 2026. The company had previously announced the closure of the insider trading window from June 30, 2026 until 48 hours after the declaration of results, in line with SEBI insider trading norms.
Likely market impact
Q1 FY27 earnings announcement could drive short-term price movement. Insider trading window remains closed, limiting insider activity till results are out.